To review empirical studies of adverse drug reactions (ADRs) reported to be associated with the use of medications generally licensed for treatment of attention deficit hyperactivity disorder (ADHD) symptoms in the pediatric population. Methods: PubMed, Embase, and PsycINFO ® databases were searched from origin until June 2011. Studies reporting ADRs from amphetamine derivates, atomoxetine, methylphenidate, and modafinil in children from birth to age 17 were included. Information about ADR reporting rates, age and gender of the child, type, and seriousness of ADRs, setting, study design, ADR assessors, authors, and funding sources were extracted.
Introduction
Psychostimulants, such as amphetamine derivates, methylphenidate, and modafinil, as well as the nonstimulant medication atomoxetine, are considered first-line medication treatment of attention deficit hyperactivity disorder (ADHD) symptoms in the pediatric population. 1 Case reports on serious cardiovascular adverse drug reactions (ADRs), sudden death, and psychiatric disorders led regulatory agencies to warn against the use 5 The use of psychostimulants, particularly methylphenidate, to treat ADHD symptoms in children has increased rapidly since the 1990s. Studies have shown that the prevalence of psychostimulant use in children in the Netherlands increased eight times from 1996 to 2006, 6 and in Germany, prescription rates of methylphenidate increased by 96% from 2000 to 2007. 7 From 1994 to 2004, the prevalence of psychostimulant use in Norwegian children increased five times, 8 while the prevalence of stimulant medication increased ten times in American children from 1987 to 1996. 9 Previous meta-analyses and reviews that evaluated the shortterm efficacy of psychostimulants on ADHD symptoms in children concluded that psychostimulants are more effective than placebo with respect to treating disturbed attention and impulsivity. 1, 10 Several articles have reported information about the safety of methylphenidate and other psychostimulants in clinical studies, 11 but to the current reviewers' knowledge no articles have systematically reviewed the occurrence of ADRs following the use of ADHD medications in the pediatric population.
The objective of this study is to review published empirical studies on the occurrence of adverse drug reactions (ADRs) associated with the use of medications generally licensed for treatment of ADHD symptoms in the pediatric population.
Methods

Literature search
A literature search was performed in PubMed, Embase, and PsycINFO ® (whole databases without language restriction) using the search terms "atomoxetine" (ATC group N06BA09), "methylphenidate" (ATC group N06BA04), "modafinil" (ATC group N06BA07), "amphetamine" (ATC group N06BA02), "psychostimulants," and "nonstimulants" combined with any of the following: "adverse drug reaction," "side effect," and "adverse event." Reference lists of identified articles were also screened for additional potentially relevant articles. For further details of the search strategy, please see Appendix 1. Literature searches were updated until September 2011.
Study selection
Using article titles as the selection basis, the first author retrieved and screened the abstracts to identify studies relevant to the study objective. Potentially relevant articles were retrieved in full text and screened for inclusion. To be considered relevant for this review, articles had to be peer reviewed and report ADRs in children in the age group 0-17 years of age associated with the use of psychostimulants.
Psychostimulants were specified as amphetamine derivates, methylphenidate, and modafinil, and nonstimulants as atomoxetine. Articles reporting ADRs from psychostimulants in mixed populations of children and adults were excluded if age-related ADR occurrence was not specified. Articles were excluded if they did not report data on ADR occurrence that made it possible to calculate rates. Hence, case reports, letters, commentaries, interim analyses, meta-analyses, and review articles were excluded. Further, articles reporting unintended events not classified as ADRs and articles on misuse were excluded, although reference lists of these studies were searched for relevant studies.
Data extraction
Data from included articles were extracted using a standard form, one for each article. The following information was recorded: authors, publication year, country, study design, dosage, comparator, monitoring period (weeks), size of study population, age and gender of included population, and ADR reporting rates in percentage. ADR reporting rates were indicated as reported in the original papers. In placebocontrolled studies, information about ADR reporting rates for placebo was also extracted. Information about who had assessed the ADRs, reported ADRs classified as being serious by the respective authors, and funding sources were also recorded. The first author extracted data, while the second author controlled and verified all cases.
Results
A total of 137 potentially relevant references were identified during the database searches and reference screenings. An overview of the review process and reasons for exclusion are displayed in Figure 1 . Sixty-eight studies were excluded after screening abstracts. Sixty-nine studies were retrieved for full text review. Of these studies, four were later excluded as they reported mixed
Dovepress
731
Review of adverse reactions for ADHD medication in children data on children and adults that could not be separated. Eight meta-analyses and four reviews of efficacy were excluded as they reported information from studies already included. Also excluded were two studies reporting data from a subgroup analysis of already included studies, and nine studies reporting ADRs as percent of children reporting an ADR. Eventually 43 articles reporting ADRs from psychostimulants in the pediatric population were included. Table 1 displays an overview of the study characteristics of included articles. The majority of studies were conducted in the United States of America (USA), the remaining in Australia, Canada, Europe, Iran, and Latin America. Atomoxetine studies were 
Design and setting
Information about ADRs was reported in clinical studies using different designs, ie, randomized parallel group studies (N = 28); [12] [13] [14] [15] [17] [18] [19] 22, 23, 28, 31, 32, [34] [35] [36] 40, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] randomized crossover studies (N = 6); 16, 23, 25, 27, 30, 39 and open-label designs (N = 9). 20, 26, 29, 33, 37, 38, 41, 50 The majority of studies were conducted in naturalistic settings at home and at school (N = 38); 12, 13, [15] [16] [17] [18] [19] [20] [21] [22] 24, 26, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] five articles reported ADRs from children participating in laboratory school protocols, 14, 23, 25, 27, 30 in which classroom sessions were organized in cycles to include 12 hours of observation. This design consisted of daily schedules of alternating classroom, meals/snacks, recess, and research activities scheduled at specific times during the day. The largest number of studies (N = 21) 31-47 concerned atomoxetine; followed by methylphenidate (N = 14; [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] modafinil (N = 7); [48] [49] [50] [51] [52] [53] [54] and amphetamine (N = 5).
12-16
Dosage and comparator
The tested dosages varied from 10 to 70 mg/day in amphetamine studies; from 5 to 72 mg/day in methylphenidate studies; from 10 to 90 mg/day in atomoxetine studies; and from 100 to 425 mg/day in modafinil studies. Placebo was used as a comparator drug in the majority of studies (N = 28), while an active comparator, was administered in nine studies. Seven open-label studies did not include a control group.
Treatment period
Treatment duration varied from 1 to 32 weeks across studies. Treatment duration varied from 2 to 4 weeks in amphetamine studies; from 1 to 10 weeks in methylphenidate studies; from 3 to 32 weeks in atomoxetine studies; and from 4 to 9 weeks in modafinil studies.
Population
A total of 8512 children were included in the clinical studies, of which 7244 children completed treatment: amphetamine (1076); methylphenidate (2092); atomoxetine (3127); and modafinil (949). The reasons for noncompletion were many, but lack of efficacy and the appearance of ADRs were the most common. The ages of the included children varied from 4 to 17 years (median 6-12 years), and the share of male patients in the studies varied from 0 to 100% (median 69%).
Type of assessor
Parents rated information about ADRs in 20 studies, and a combination of teacher/parent (five studies), [16] [17] 30, [48] [49] and patient/parent (three studies). 27, 49, 51 The articles specified only limited information about applied ADR scales and the classification systems used.
Funding source
In almost all studies the funding source was the manufacturer of the respective medications, and only four studies were publicly funded. Additionally, a large number of the studies were conducted by the same groups of authors who declared conflicts of interest. The majority of the authors received contributions from the pharmaceutical companies producing the medications in return for activities, such as providing scientific advice and making oral and poster presentations at scientific meetings.
ADRs by type and occurrence
Tables 2-5 display the ADR reporting rates listed in the included studies for each type of psychostimulant. ADRs of similar type and wording were aggregated in a common category in order to clarify data presentation. The aggregated categories were: weight changes (changes in weight, weight decreased, weight increased, decrease in weight); gastrointestinal pain (abdominal pain, upper abdominal pain, gastrointestinal pain); anxiety (anxiety, anxiousness); influenza (influenza, flu syndrome); tics (tics, motor tics, facial tics); blood pressure changes (diastolic blood pressure, changes in blood pressure); sleeping problems (awake during the night, difficulty falling asleep, sleep disturbance, delayed onset of sleep); changes in heart rate (racing heart, changes in heart rate). Thirty-one categories of ADRs were reported for amphetamine derivates (Table 2) ; 65 categories for methylphenidate formulations (Table 3) ; 55 categories for atomoxetine (Table 4) ; and 38 categories for modafinil ( Table 5 ). The following ADRs were most frequently reported for all four psychostimulants: decrease in appetite, gastrointestinal pain, and headache.
ADRs by seriousness
The majority of reported ADRs were categorized by the authors/investigators as nonserious. 
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Discussion
This is the first study to systematically review the empirical literature on the occurrence of ADRs reported for ADHD medications in the pediatric population. Information about ADRs from psychostimulants and the nonstimulant atomoxetine was reported in clinical studies of short duration, primarily conducted in 6-to 12-year-old boys, and particularly in the USA. The most frequently reported ADRs were decrease in appetite, gastrointestinal pain, and headache. A large number of studies were conducted by the same groups of authors and sponsored by the pharmaceutical companies manufacturing the respective medications.
Design and setting
Although the review process found a large number of small clinical trials exploring the efficacy of ADHD medications in the pediatic population, only a minor share of these studies reported information about ADRs. The studies included in this article were similar in design and setting, treatment duration, as well as number, age, and gender of included patients. The reliability of the studies may be questioned as the number of reported ADRs varied widely for identical and similar study designs. Further exploration of these questions would require access to the original study material. Large variations in ADR reporting rates were observed between studies and therapeutic groups, and similar types of ADRs were reported for the individual ADHD medications. It is puzzling that large numbers of specific ADRs are reported in some studies, but few if any in others. These findings question the relevance of the many small clinical trials conducted on the medications, particularly atomoxetine and methylphenidate, as they are not designed to measure long-term efficacy and safety. 55 Almost all of these clinical trials were sponsored by the pharmaceutical companies producing the subject medications, and therefore, the current reviewers encourage these companies to make information about the ADRs reported in said clinical trials accessible to the public.
Seriousness of reported ADRs
Only a small number of serious ADRs were reported. However, in several of the included studies a large number of children withdrew due to experiencing ADRs, and therefore, the actual number of serious ADRs occurring from the use of ADHD medications might be higher, and some types of ADRs may not have been reported. Information about ADR incidence in the monitored population was only reported if the incidence was above 2% and/or 5%; consequently, information about rarely occurring ADRs is not included. Another issue is that information about definitions and scales to define and evaluate events occurring during the clinical trials is not reported in the articles, thus making it impossible to react to this information. Therefore, the regulatory agencies are encouraged to allow access to the original clinical protocols, so that all information reported for ADHD medications can be made public. A previous study has shown that there are large discrepancies between the data reported in clinical trial protocols and data published in scientific journals. 56 
Long-term safety aspects of psychostimulant use
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Review of adverse reactions for ADHD medication in children Table 4 Adverse drug reaction reporting rates (%) for atomoxetine by category and study there is a need for long-term efficacy and safety studies. 1 The lack of sufficient knowledge about ADRs at the point of licensing of new medicines makes spontaneous ADR reporting an important source of information about medicine safety. 57 As clinical trials in the pediatric population are limited, clinicians and health authorities must rely on spontaneous reports as the main source of information about previously unknown ADRs. 57 However, the current review did not find any studies about ADRs from the use of psychostimulants reported to any national ADR databases. Systematic analyses of ADRs reported to national databases are necessary, as these databases constitute a critical (and underestimated) source of important data, especially information about new, serious, and rarely occurring ADRs. Further studies of data from large databases, ie, the World Health Organization/Uppsala Monitoring Centre VigiBase™ (Uppsala, Sweden) or the European Medicines Agency EudraVigilance (London, United Kingdom [UK]) databases, are recommended in order to increase knowledge about ADRs from the use of ADHD medications.
Strengths and limitations of this review
The included studies were conducted over a period of approximately 20 years in different countries, with a great deal of inconsistency in observing and classifying the type and seriousness of reported ADRs. Information about the seriousness of the reported ADRs was extracted from the included studies, and it was not possible for the review to evaluate these ratings, nor to estimate ADRs in terms of effect sizes, as the review did not have access to the original data material. A major limitation of this study is that it is unknown to what extent the causality of these ADRs can be confirmed, and this has implications for the interpretation of the findings in the review. A large number of published clinical studies were not included in this review because these articles did not report information about ADRs, despite the fact that pharmaceutical companies had a legal obligation to monitor ADRs in clinical trials, and therefore, these data must exist. As the clinical trials were mainly sponsored by the pharmaceutical companies that produce the medications, these companies are urged to make these data accessible to the public.
Conclusion
Reported ADRs from the use of psychostimulants in the pediatric population were generally found in clinical trials of short duration. Since ADHD medications are prescribed for long-term treatment there is a need for long-term safety
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The authors report no conflicts of interest in this work. studies. Considering the widespread and increasing use of these medications in children, greater care must be taken when prescribing these medications for long-term use. Further studies of spontaneous reports submitted to national and international databases are recommended in order to increase knowledge about ADRs from the use of psychostimulants in the pediatric population. Pharmaceutical companies should make all information about ADRs reported for ADHD medications accessible to the public. Additionally, the impact of the link between researchers and the manufacturers of the medications needs to be studied.
